Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
OBIO US​

Orchestra BioMed Holdings, Inc.(OBIO US)

$5.59+0.122.19%Ext:$5.67+0.081.49%(Market Closed · 23:55:35 UTC)

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Orchestra BioMed Holdings, Inc. — Company Profile

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
David Hochman
Headquarters
New Hope, PA, US
IPO Date
Aug 4, 2020
Employees
86
Website
orchestrabiomed.com

Key Metrics

Price
$5.95
Market Cap
$356.29M
Revenue (TTM)
$110.00K
Net Income (TTM)
$-20691000.00
EPS (TTM)
-0.54
P/E (TTM)
-6.52
P/B (TTM)
6.99
Dividend Yield
0.00%
ROE (TTM)
-40.60%
ROA (TTM)
-20.56%
Operating Margin
-200.69%
Beta
1.02

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Website
orchestrabiomed.com
Location
New Hope, PA, US
Phone215 862 5797
Employees86
CEODavid Hochman
Sector
Health Care
Industry
Pharmaceuticals
IPO DateAug 4, 2020

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

News

  • Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB22 Oct
  • Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy1 Oct
  • OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures29 Sep
  • Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?21 Sep
  • Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 202616 Sep
  • Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics15 Sep
  • Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2 Sep
  • Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference27 Aug
  • Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference20 Aug
  • Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates10 Aug
  • Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO25 Jul

Key Stats

Trading

Px/Chg 1D$5.95 / -6.30%
Avg Volume276.73K
Beta1.02
Mkt Cap356.29M
FD Mkt Cap302.40M

Float

Shrs Out/Float59.88M / 41.26M
Short Float0.05%
Days to Cover2.71
Stock Repurchased$0.00

Current Valuation

EV371.33M
EV/EBITDA-7.05
EV/Sales11.35
P/B6.99
P/S10.89
FCF Yield-6.27%
ROE-40.60%
ROA-20.56%
Current Ratio7.03

Estimates

P/E-6.52
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.94-11.73-3.19-1.6024.04-17.22
Price / Sales689.83111.6156.7036.994.863,239.00
Price / Book Value4.437.512.302.962.376.99
Price / Free Cash Flow-19.93-13.20-3.39-1.92-65.18-15.94
ENTERPRISE VALUE METRICS
Enterprise Value227.0386.4127.691.8157.7371.3
Enterprise Value / Sales714.25109.3746.2434.825.103,375.74
Enterprise Value / EBITDA-2.47-11.91-2.49-1.4422.24-18.77
Enterprise Value / EBIT-2.39-11.83-2.48-1.4322.50-18.69

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-0.83.52.82.633.5
Gross Income—-1.03.22.62.433.3
EBITDA24.1%-21.6-32.4-51.2-64.0-51.2
EBIT24%-21.8-32.7-51.5-64.3-51.6
Net Income23%-23.0-33.6-49.1-61.0-52.7
EPS (Diluted)193.9%-0.02-1.32-1.48-1.66-1.38
BALANCE SHEET
Cash & ST Inv76.8%10.983.887.666.8106.5
Total Assets70.7%13.595.695.276.2114.9
Total Liabilities-11.7%84.843.027.243.251.5
Total Shareholder Equity—-71.252.568.033.063.4
CASH FLOW
Net Operating Cash Flow26%-19.4-29.3-46.1-50.6-49.0
Cap Ex15.6%-0.3-0.6-0.1-0.3-0.5
Free Cash Flow25.9%-19.7-29.9-46.2-50.8-49.5

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)5.55
Basic Shares59.88
Market Cap332.3
Diluted Shares38.39
Fully Diluted Shares Outstanding38.39
Fully Diluted Market Cap213.1
+Consolidated Debt33.6
−In-the-Money Convertible Debt—
+Capital Leases0.7
+Operating Leases—
−Cash & Equivalents-28.4
−Short-term Investments-66.0
+Total Preferred9.8
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value347.4

Segment data

Revenue

by Products and services

  • Product100%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US